Published in Curr Clin Pharmacol on May 01, 2013
Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? Am J Cancer Res (2014) 1.03
Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation. Mol Endocrinol (2016) 0.88
RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs (2015) 0.82
A(nother) scientific strategy to prevent breast cancer in postmenopausal women by enhancing estrogen-induced apoptosis? Menopause (2014) 0.80
The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy. Mol Cell Endocrinol (2015) 0.80
CB2 cannabinoid receptor is a novel target for third-generation selective estrogen receptor modulators bazedoxifene and lasofoxifene. Biochem Biophys Res Commun (2013) 0.79
New horizons in treatment of osteoporosis. Daru (2017) 0.79
Aptamer-Assisted Detection of the Altered Expression of Estrogen Receptor Alpha in Human Breast Cancer. PLoS One (2016) 0.77
Advances in Controlled Drug Delivery for Treatment of Osteoporosis. Curr Osteoporos Rep (2016) 0.77
The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators. Steroids (2014) 0.77
Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer. J Med Chem (2015) 0.77
Cyclopia extracts act as ERα antagonists and ERβ agonists, in vitro and in vivo. PLoS One (2013) 0.76
New insights into treatment of osteoporosis in postmenopausal women. RMD Open (2015) 0.76
Kinetically Defined Mechanisms and Positions of Action of Two New Modulators of Glucocorticoid Receptor-regulated Gene Induction. J Biol Chem (2015) 0.76
Are estrogen-related drugs new alternatives for the management of osteoarthritis? Arthritis Res Ther (2016) 0.76
The SMRT coregulator enhances growth of estrogen receptor-α-positive breast cancer cells by promotion of cell cycle progression and inhibition of apoptosis. Endocrinology (2014) 0.76
Age-associated Cognitive Decline: Insights into Molecular Switches and Recovery Avenues. Aging Dis (2016) 0.76
Estrogen-responsive genes encoding egg yolk proteins vitellogenin and apolipoprotein II in chicken are differentially regulated by selective estrogen receptor modulators. Theriogenology (2015) 0.75
Novel Promising Estrogenic Receptor Modulators: Cytotoxic and Estrogenic Activity of Benzanilides and Dithiobenzanilides. PLoS One (2016) 0.75
Bilateral macular edema in a patient treated with tamoxifen: a case report and review of the literature. Case Rep Ophthalmol (2014) 0.75
Targeted therapies: Any surprises from selective oestrogen-receptor modulators? Nat Rev Clin Oncol (2013) 0.75
Ligand Accessibility and Bioactivity of a Hormone-Dendrimer Conjugate Depend on pH and pH History. J Am Chem Soc (2015) 0.75
Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy. Int J Womens Health (2016) 0.75
Estrogen Receptor Ligands: A Review (2013-2015). Sci Pharm (2016) 0.75
PPARβ/δ selectively regulates phenotypic features of age-related macular degeneration. Aging (Albany NY) (2016) 0.75
The Dual Estrogen Receptor α Inhibitory Effects of the Tissue-Selective Estrogen Complex for Endometrial and Breast Safety. Mol Pharmacol (2015) 0.75
Tamoxifen: an FDA approved drug with neuroprotective effects for spinal cord injury recovery. Neural Regen Res (2016) 0.75
Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence. Menopause (2015) 0.75
Prediction of selective estrogen receptor beta agonist using open data and machine learning approach. Drug Des Devel Ther (2016) 0.75
Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity. Front Pharmacol (2016) 0.75
Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes. Breast Cancer Res (2014) 0.75
Androgen Receptor Expression in an Indian Breast Cancer Cohort with Relation to Molecular Subtypes and Response to Neoadjuvant Chemotherapy - a Prospective Clinical Study. Breast Care (Basel) (2017) 0.75
Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications. Int J Mol Sci (2017) 0.75
Compounds from Cynomorium songaricum with Estrogenic and Androgenic Activities Suppress the Oestrogen/Androgen-Induced BPH Process. Evid Based Complement Alternat Med (2017) 0.75
Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ. Cancer Prev Res (Phila) (2017) 0.75
GPER modulators: Opportunity Nox on the heels of a class Akt. J Steroid Biochem Mol Biol (2017) 0.75
Effects of estrogen receptor modulators on cytoskeletal proteins in the central nervous system. Neural Regen Res (2017) 0.75
Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia. Osteoporos Int (2016) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell (2000) 11.10
Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A (1996) 10.94
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 10.62
Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science (1995) 10.42
Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology (1997) 10.08
The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell (1998) 9.96
Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA (1999) 9.18
Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (1997) 9.09
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst (2005) 7.70
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science (1997) 6.60
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst (2004) 6.55
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol (2009) 6.51
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med (2006) 6.14
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) (2010) 5.81
Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med (2010) 5.60
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst (2003) 4.45
Sequence and expression of human estrogen receptor complementary DNA. Science (1986) 4.36
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst (2007) 4.11
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
The effects of tibolone in older postmenopausal women. N Engl J Med (2008) 3.96
Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev (2004) 3.74
Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol (2011) 3.73
The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology (1999) 3.67
A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer (1971) 3.57
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med (1992) 3.54
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat (2004) 3.40
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst (2007) 3.39
Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ (2000) 3.30
Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov (2003) 3.07
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol (1977) 3.03
Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res (2004) 2.67
The expanding cosmos of nuclear receptor coactivators. Cell (2006) 2.57
Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol (1998) 2.55
Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J (2001) 2.51
Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation (1998) 2.47
Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet (1989) 2.46
The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem (2001) 2.45
New synthetic agent for the induction of ovulation: preliminary trials in women. Br Med J (1971) 2.45
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol (2005) 2.41
Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst (1993) 2.38
Induction of ovulation with MRL/41. Preliminary report. JAMA (1961) 2.22
Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res (2001) 2.21
MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res (1997) 2.12
Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J (1973) 2.06
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst (1990) 1.97
A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil (1967) 1.94
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids (2006) 1.89
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther (2006) 1.84
Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res (2008) 1.79
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst (2010) 1.79
A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer (1989) 1.78
Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res (1990) 1.78
Biochemical pharmacology of antiestrogen action. Pharmacol Rev (1984) 1.74
Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer (2007) 1.71
Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat (1987) 1.70
Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol (2006) 1.68
Nuclear mechanisms of estrogen action. Effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing. J Biol Chem (1978) 1.66
Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol (2005) 1.64
Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol (2003) 1.59
Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause (2006) 1.59
Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res (2004) 1.58
Estrogen receptors: therapies targeted to receptor subtypes. Clin Pharmacol Ther (2010) 1.57
Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest (1994) 1.55
Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med (1991) 1.55
Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology (2005) 1.52
Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res (1987) 1.52
Comparative analyses of mechanistic differences among antiestrogens. Endocrinology (1999) 1.52
Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer (2008) 1.50
Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology (2000) 1.50
E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia (2006) 1.49
Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res (1988) 1.44
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J Med Chem (2003) 1.44
Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause (2009) 1.42
EFFECTS OF TRIPARANOL (MER-29) ON CHOLESTEROL BIOSYNTHESIS AND ON BLOOD STEROL LEVELS IN MAN. J Clin Invest (1961) 1.41
Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause (2009) 1.39
A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol. Endocrinology (1958) 1.37
Effect of estrogen therapy on gallbladder disease. JAMA (2005) 1.36
Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. Endocrinology (1998) 1.36
Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res (1993) 1.33
Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res (2008) 1.32
Transcriptional regulation by steroid receptor coactivator phosphorylation. Endocr Rev (2005) 1.32
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol (1995) 1.31
Molecular biology. Little molecules with big goals. Science (2006) 1.29
Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer (1980) 1.27
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) (2010) 5.81
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst (2003) 2.18
International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev (2006) 2.15
Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst (2005) 2.10
Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem (2006) 2.03
The estrogen receptor: a model for molecular medicine. Clin Cancer Res (2003) 1.99
The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J Biol Chem (2005) 1.96
Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst (2003) 1.92
Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics. Genome Res (2012) 1.85
Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer (2004) 1.82
Early breast cancer. Lancet (2009) 1.82
Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res (2009) 1.75
Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A (2009) 1.75
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol (2012) 1.71
Most plastic products release estrogenic chemicals: a potential health problem that can be solved. Environ Health Perspect (2011) 1.63
Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biol Ther (2004) 1.63
The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol (2004) 1.55
Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res (2005) 1.50
Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst (2002) 1.50
Estrogen-related receptors as emerging targets in cancer and metabolic disorders. Curr Top Med Chem (2006) 1.39
The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res (2010) 1.36
Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway. Mol Cancer Res (2007) 1.36
Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci U S A (2011) 1.33
Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res (2006) 1.23
Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs). Breast Dis (2006) 1.22
Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Clin Cancer Res (2008) 1.18
MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions. J Biol Chem (2003) 1.15
3-Methylcholanthrene and other aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha. Cancer Res (2006) 1.14
Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis. Breast Cancer Res (2008) 1.14
Progress in endocrine approaches to the treatment and prevention of breast cancer. Maturitas (2011) 1.11
Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha. Int J Cancer (2003) 1.11
Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anticancer Agents Med Chem (2009) 1.09
c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells. Cancer Res (2013) 1.09
Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J Steroid Biochem Mol Biol (2005) 1.09
Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int J Oncol (2009) 1.08
Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J Biol Chem (2004) 1.07
Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach? Eur J Cancer (2009) 1.07
Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen. J Med Chem (2010) 1.05
Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin Breast Cancer (2008) 1.05
Steroid receptors and their role in the biology and control of breast cancer growth. Semin Oncol (2006) 1.05
The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol (2002) 1.04
Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res (2002) 1.04
The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1. Mol Pharmacol (2011) 1.04
Estrogen regulation of X-box binding protein-1 and its role in estrogen induced growth of breast and endometrial cancer cells. Horm Mol Biol Clin Investig (2010) 1.03
Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. J Biol Chem (2002) 1.03
Selective estrogen receptor modulators and phytoestrogens. Planta Med (2008) 1.02
Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Mol Cancer Ther (2007) 1.01
Surgeon-performed ultrasound in the management of thyroid malignancy. Am Surg (2004) 1.01
Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. Menopause (2013) 1.00
Interactions between cognition and circadian rhythms: attentional demands modify circadian entrainment. Behav Neurosci (2009) 1.00
SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord (2007) 0.99
Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells. Eur J Cancer (2008) 0.99
Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. Trends Mol Med (2002) 0.98
Gonadal hormone effects on entrained and free-running circadian activity rhythms in the developing diurnal rodent Octodon degus. Am J Physiol Regul Integr Comp Physiol (2006) 0.97
Characteristics of salivary profiles of oestradiol and progesterone in premenopausal women. J Endocrinol (2005) 0.97
Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Adv Exp Med Biol (2008) 0.97
MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis. Cancer Res (2005) 0.95
Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2. J Steroid Biochem Mol Biol (2004) 0.94
Period gene expression in the diurnal degu (Octodon degus) differs from the nocturnal laboratory rat (Rattus norvegicus). Am J Physiol Regul Integr Comp Physiol (2008) 0.94
Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines. Eur J Cancer (2012) 0.94
Bioluminescence imaging for assessment and normalization in transfected cell arrays. Biotechnol Bioeng (2007) 0.94
Aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha in MCF-7 breast cancer cells. Biol Chem (2006) 0.93
Differential effects of prenatal testosterone timing and duration on phenotypic and behavioral masculinization and defeminization of female sheep. Biol Reprod (2008) 0.93
Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells. PLoS One (2011) 0.93
In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer. Breast Cancer (2002) 0.92
Prenatal testosterone and dihydrotestosterone exposure disrupts ovine testicular development. Reproduction (2011) 0.92
Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations. Horm Mol Biol Clin Investig (2012) 0.92
Prenatal stress differentially affects habituation of corticosterone responses to repeated stress in adult male and female rats. Horm Behav (2005) 0.91
A prospective study of variability in mammographic density during the menstrual cycle. Breast Cancer Res Treat (2009) 0.90
Bidirectional interactions between circadian entrainment and cognitive performance. Learn Mem (2012) 0.90
Sex-specific susceptibility to cocaine in rats with a history of prenatal stress. Physiol Behav (2009) 0.89
Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Eur J Cancer (2010) 0.89
Complete androgen insensitivity syndrome: the role of the endocrine surgeon. Am Surg (2005) 0.89
Interaction of the aryl hydrocarbon receptor ligand 6-methyl-1,3,8-trichlorodibenzofuran with estrogen receptor alpha. Cancer Res (2004) 0.89
Ovarian hormones influence olfactory cue effects on reentrainment in the diurnal rodent, Octodon degus. Horm Behav (2004) 0.88
Female meadow voles (Microtus pennsylvanicus) demonstrate same-sex partner preferences. J Comp Psychol (2003) 0.88
Changes in circadian rhythms during puberty in Rattus norvegicus: developmental time course and gonadal dependency. Horm Behav (2011) 0.88
Is tamoxifen the Rosetta stone for breast cancer? J Natl Cancer Inst (2003) 0.88
Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells. Int J Oncol (2006) 0.87
Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens. Cancer Res (2003) 0.87
The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death. Exp Biol Med (Maywood) (2004) 0.87
5,6-Epoxy-cholesterols contribute to the anticancer pharmacology of tamoxifen in breast cancer cells. Biochem Pharmacol (2013) 0.86
Inhibiting cortisol response accelerates recovery from a photic phase shift. Am J Physiol Regul Integr Comp Physiol (2004) 0.86
Long-term exposure of female sheep to physiologic concentrations of estradiol: effects on the onset and maintenance of reproductive function, pregnancy, and social development in female offspring. Biol Reprod (2006) 0.86
Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. Int J Oncol (2007) 0.86
Circadian dependence of corticosterone release to light exposure in the rat. Physiol Behav (2007) 0.86
The neuroendocrine control of the circadian system: adolescent chronotype. Front Neuroendocrinol (2012) 0.85
Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance. Int J Oncol (2010) 0.85
Optimizing the antihormonal treatment and prevention of breast cancer. Breast Cancer (2007) 0.85
Time to pay attention: attentional performance time-stamped prefrontal cholinergic activation, diurnality, and performance. J Neurosci (2012) 0.85
Defining the conformation of the estrogen receptor complex that controls estrogen-induced apoptosis in breast cancer. Mol Pharmacol (2014) 0.85
Chemoprevention of breast cancer: current and future prospects. Cancer Metastasis Rev (2002) 0.85
Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clin Cancer Res (2006) 0.85
Restraint stress delays reentrainment in male and female diurnal and nocturnal rodents. J Biol Rhythms (2005) 0.84
The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis. Curr Signal Transduct Ther (2009) 0.84
Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells. J Biol Chem (2001) 0.84
Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant. J Steroid Biochem Mol Biol (2006) 0.84
Retracted Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert Opin Pharmacother (2011) 0.83